A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome.

Trial Profile

A Phase 2 Trial of MLN8237, an Oral Aurora A Kinase Inhibitor, in Adult Patients With Acute Myelogenous Leukemia and High-Grade Myelodysplastic Syndrome.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2012

At a glance

  • Drugs Alisertib (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 11 Jan 2012 Actual end date changed from Sep 2010 to Sep 2011 as reported by ClinicalTrials.gov.
    • 13 Oct 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
    • 13 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top